​

Funding Round

Series B - Proteostasis Therapeutics

Series B - Proteostasis Therapeutics

Investment Firm

Overview

Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.

Announced Date

Sep 08, 2015

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Cormorant Asset Management

Cormorant Asset Management

Cormorant Asset Management is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Rock Springs Capital

Rock Springs Capital

Rock Springs Capital is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Participant Investors

7

Investor Name
Participant InvestorSanofi Ventures
Participant InvestorNovartis Venture Fund
Participant InvestorF-Prime Capital
Participant InvestorHealthCare Ventures
Participant InvestorNew Enterprise Associates

Round Details and Background

Proteostasis Therapeutics raised $37000000 on 2015-09-08 in Series B

Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Oct 24, 2018
Post-IPO Equity - Proteostasis Therapeutics
-74.3M
Sep 08, 2015
Series B - Proteostasis Therapeutics
7-37.0M
Aug 15, 2014
Debt Financing - Proteostasis Therapeutics
-3.0M
Aug 25, 2008
Series A - Proteostasis Therapeutics
5-45.0M

Recent Activity

There is no recent news or activity for this profile.